biotech
biotech Articles
Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial of fasinumab in patients with chronic pain from osteoarthritis...
Published:
Last Updated:
Summit Therapeutics shares made a solid gain early on Thursday after the firm announced that it was awarded an additional $12 million under its contract with the Biomedical Advanced Research and...
Published:
Last Updated:
The latest monthly Merrill Lynch RIC Report is quite favorable on the health care sector as an opportunity for investors. Here we identify some of the top health care picks.
Published:
Last Updated:
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Published:
Last Updated:
Spark Therapeutics took a massive hit on Tuesday that wiped out about 28% of the share price in the wake of its second-quarter earnings report.
Published:
Last Updated:
Whether you are a consumer or an employer, there is a pretty good chance you would like to have lower costs of health care.
Published:
Last Updated:
Gemphire shares were more than halved on Tuesday after the company provided an update in regards to the clinical hold on gemcabene with respect to clinical trials of longer than six months in...
Published:
Last Updated:
Ovid Therapeutics shares were crushed to start the week even though the company announced positive midstage results for its Angelman syndrome study.
Published:
Last Updated:
Protagonist Therapeutics shares saw a solid gain on Monday after the firm announced positive results from its midstage trial in patients with ulcerative colitis. This comes after some controversy...
Published:
Last Updated:
Sienna Biopharmaceuticals shares pulled back on Monday after the company announced less than favorable results from a couple of its acne trials.
Published:
Last Updated:
RedHill Biopharma shares made a solid gain early on Monday after the firm announced positive results from its late-stage trial in Crohn’s disease.
Published:
Last Updated:
Celgene released better-than-expected quarterly results and updated guidance before the markets opened on Thursday.
Published:
Last Updated:
Gilead reported its most recent quarterly results after the markets closed on Wednesday. The major biotech posted $1.91 in earnings per share (EPS) and $5.65 billion in revenue, versus with consensus...
Published:
Last Updated:
Gilead is scheduled to release its second-quarter financial results after the markets close on Wednesday, and analyst expectations are low.
Published:
Last Updated:
The July 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Published:
Last Updated: